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demonstrated an inverse correlation between platelet count and
anti-GPIIb/IIIa antibody-producing B cell frequency. Thrombo-
cytopenia mediated by anti-platelet antibodies should be included
into differential diagnosis for prolonged thrombocytopenia after
allo-HSCT.
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FEF25-75% AS A SPIROMETRIC VARIABLE IN PULMONARY FUNCTION
TESTING (PFT) IS PREDICTIVE FOR THE DIAGNOSIS OF OBLITERATIVE
BRONCHIOLITIS (OB) FOLLOWING MYELOABLATIVE ALLOGENEIC HE-
MATOPOIETIC STEM CELL TRANSPLANT (HSCT)
Burgos-Fuster, L.M., Koyama, T., Milestone, A., Mineishi, S., Jagasia,
M., Vusirikala, M., Goodman, S., Schuening, F., Greer, J.P., Chinra-
tanalab, W., Brandt, S., Ruffner, K., Morgan, D.S., Stein, R.S.,
Kassim, A.A. Vanderbilt University Medical Center, Nashville, TN;
Veterans Affairs Medical Center, Nasville, TN
Introduction: Following allogeneic HSCT, a major cause of
obstruction is OB (frequency, 8-33%). Diagnosis is histologic, but
often presumptive, based on clinical features, radiographic and
PFT changes showing obstruction, hyperinﬂation and gas trap-
ping. OB is associated with chronic, but not acute graft-versus-host
disease (cGVHD/aGVHD). A 5% decline in percent predicted
forced expiratory volume in 1 second (FEV1), FEV1/FVC (forced
vital capacity)  0.7 or 10% fractional drop from previous best
PFT was suggestive of OB in previous studies. It is yet to be
deﬁned which spirometric measurement is most suggestive for the
presence of OB. Forced expiratory ﬂow rates (FEF25-75%), with
30% decline from baseline was found to be more sensitive than
FEV1 in diagnosing OB following single lung transplant [Nathan,
et al, 2003 J Heart and Lung Transplantation 22(4): 427]. FEF25-
75% has never been evaluated following allogeneic HSCT. Meth-
ods: We retrospectively reviewed PFT data on 48 adult patients
undergoing HSCT from 1998-2003, who survived for at least 12
months and had pre and post-transplant PFT within 1-year of
HSCT. Median age was 42 years (range, 20-57), and 54% were
male. Forty-seven patients had malignant hematologic disorders.
The conditioning regimen was TBI-based in 34 (73%) patients,
and 13 received chemotherapy only. Marrow and peripheral blood
stem cells were used in 22 and 26 patients respectively. Results:
Incidence of aGVHD was 52%, (gradeI-II/III-IV: 88%/12%),
12% of patients had cGVHD (limited/extensive: 69%/13%). Ten
patients (21%) had a diagnosis of OB (8-histologicaly, 2-based on
signs and symptoms). Spirometric measurements considered as
predictor variables included diffusion capacity for carbon monox-
ide (DLCO), FEV1, total lung capacity (TLC), FEF 25-75%.
There was no signiﬁcant association between diagnosis of OB and
age, GVHD, stem cell source, preparatory regimen, TLC or
DLCO. A backward elimination model building procedure for a
logistic regression identiﬁed FEF25-75% as the sole signiﬁcant
explanatory variable. This model suggests that with a 40% decrease
or more in FEF 25-75% compared to pre-transplant value, the
estimated probability of the diagnosis of OB would be 50% or
higher. Conclusion: A decrease in FEF 25-75% of  of 40%, in
the absence of other non-infectious pulmonary complications, was
highly suggestive in allogeneic HSCT patients for the diagnosis of
OB. We plan to evaluate our ﬁndings in a prospective study.
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PSYCHOSOCIAL PREDICTORS OF AUTOLOGOUS BONE MARROW
TRANSPLANT PATIENTS’ FUNCTIONING: INDICATIONS FOR EARLY IN-
TERVENTION
Lanza Hurley, C.1, Mumby, P.B.2, Di Iorio, S.2, Stiff, P.J.2 1. Loyola
University Chicago, Chicago, IL; 2. Loyola University Medical Center,
Maywood, IL
Compared to mixed oncology samples, estimates of emotional
distress are considered to be higher for patients treated by bone
marrow transplant (BMT). This increased risk has been met by
limited research investigating psychosocial predictors of BMT psy-
chological and physical sequelae. Such analysis may serve to better
inform bone marrow treatment centers in identiﬁcation of patients
at risk for transplant-related psychological and physical morbidity.
Data from 210 consecutive adult cancer patients who underwent
autologous BMT at a large Midwestern cancer center were uti-
lized. There were 73 males and 137 females (mean age  48.25).
Prior to transplant, patients completed a BMT clinic questionnaire
and the Symptom-Checklist 90-Revised (SCL-90-R). Stepwise
multiple regression analyses were performed using the depression
subscale of the SCL-90-R, coping, and total social support (i.e.,
structural and perceived) as dependent variables. Age and total days
from diagnosis to treatment were controlled. Gender predicted
depressive symptomatology (beta  .216, t  2.187, p  .03)
and total social support (beta  .206, t  2.084, p  .039), with
males endorsing more depressive symptoms than females and fe-
males listing more structural support than males. Marital status
predicted social support speciﬁc to BMT (beta  .368, t 
4.538, p  .001) with married patients reporting fewer supports
through BMT than their unmarried counterparts. Females re-
ported larger support networks than males. Previous psychological
treatment predicted depressive symptomatology (beta  6.165, t 
2.874, p  .005) and improved coping (beta  .493, t  3.766,
p  .001). That married persons mainly rely upon spouses for
support may have important caregiver respite implications. In
addition, psychotherapy may improve patients’ conﬁdence in their
ability to cope with BMT despite increased levels of depression
prior to BMT. These ﬁndings suggest early psychological inter-
ventions for patients undergoing BMT may improve coping re-
sources for dealing with the stress of the process. Further analyses
will investigate whether these psychosocial factors predict BMT-
related psychological and physical morbidity.
185
PROSPECTIVE STUDY OF MAJOR SALIVARY GLANDS IN PATIENTS SUB-
MITTED TO BONE MARROW TRANSPLANTATION-PRELIMINARY RE-
SULTS
Coracin, F.L.1, Camargo, E.E.2, Vigorito, A.C.1, Gasparetto, P.F.1,
Peterson, D.E.3, Correa, M.E.P.1, De Souza, C.A.1 1. Hematology and
Blood Transfusion Center-State University of Campinas-UNICAMP,
Campinas, Sa˜o Paulo, Brazil; 2. Division of Nuclear Medicine-State
University of Campinas-UNICAMP, Campinas, Sa˜o Paulo, Brazil; 3.
School of Dental Medicine-University of Connecticut, Farmington, CT
Salivary gland involvement in chronic GVHD (cGVHD) is in-
dicated by increased dryness of the oral cavity, abnormalities in the
saliva and histopathological changes in labial minor salivary glands.
Salivary changes leading to 45-60% of hyposalivation have been
reported in cGVHD in both and human studies. Fibrosis and
inﬂammatory inﬁltration were the mostly important histopatho-
logical changes observed in oral cGVHD minor salivary glands
biopsies. The aim of this study was to evaluate prospectively the
side effects of the conditioning regimen used for allogeneic BMT
on major salivary gland using scintigraphy with Gallium-67 and
technetium-99m-pertechnetate. This is an ongoing study per-
formed in the University Hospital of State University of Campi-
nas–Brazil. Between March 2002 until July 2003, ﬁfteen Chronic
Myeloid Leukemia (CML) and three Severe Aplastic Anemia
(SAA) patients submitted to conventional allogeneic BMT were
enrolled. Ten of them are female and 8 are male and the median
age of this group was 39 yo (31-55 years). Conditioning regimen
and GVHD prophylaxis used following Institutional protocols.
Scintigraphic exams was performed at Division of Nuclear Medi-
cine, using 10mCi of Technetium-99m pertechnetate and 3mCi of
Gallium-67, intravenously. Gallium-67 images were done after 48
hours of intravenous injection. Gallium-67 and Technetium data
are summarized in Table 1 and Table 2, respectively. These data
are preliminary. Scintigraphy showed an increase of inﬂammatory
reaction and a functional deﬁcit in major salivary glands after
BMT. Salivary glands dysfunction maybe due to cGVHD or side-
effect related to high dose chemotherapy. It is not clear in the
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literature the differentiation between salivary gland dysfunc-
tion due to cGVHD and long-term related high dose chemo-
therapy.
LYMPHOMA/MULTIPLE MYELOMA
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A PILOT STUDY OF MYELOABLATIVE (MA) AUTOLOGOUS STEM CELL
TRANSPLANTATION (AUTOSCT) FOLLOWED BY REDUCED INTENSITY
(RI) ALLOGENEIC TRANSPLANTATION (ALLOSCT) IN CHILDREN AND
YOUNG ADULTS WITH RELAPSED/REFRACTORY LYMPHOMA
Bradley, M.B., Cooney, E., Harrison, L., George, D., Garvin, J., Del
Toro, G., Bessmertny, O., Cheung, Y.-K., Weiner, M., Kelly, K.,
Gewanter, R., Skerrett, D., Cairo, M.S. Children’s Hospital of New
York-Presbyterian, Columbia University, New York, NY
AlloSCT may be beneﬁcial to patients with relapsed Hodgkin’s
disease (HD) and non-Hodgkin’s lymphoma (NHL) by providing
a graft vs HD effect. MA AlloSCT is however associated with a
high incidence of regimen-related mortality (RRM) (Jones et al,
Blood 77:649, 1991). Carella et al (JCO 18:3918, 2000) demon-
strated the feasibility of MA AutoSCT followed by RI AlloSCT in
adults with refractory HD. We investigated MA AutoSCT fol-
lowed by RI AlloSCT in relapsed pediatric HD/NHL. Patients
were entered post reinduction therapy (2 CR  2 PR after Ifos/
Carbo/Etop, 1 CR after Ifos/Vinorelbine and 1 PR after Topo/
Ifos/Carbo). MA: Cyclo 1500 mg/m2  4d, BCNU 100 mg/m2 
3d, VP-16 800 mg/m2  3d, and AutoSCT. Patients with CD20
lymphoma (5/6) received Rituximab (375 mg/m2/wk/4) and 6
patients received IFRT (2-3 Gy). RI: Flu 30 mg/m2  5d, Bu 3.2
mg/kg  2d, and Thymoglobulin® 2.0 mg/kg  4d (UCB recip-
ients only) and AlloSCT (1 related 6/6 PBSC, 5 4/6 UCB). GVHD
prophylaxis: FK506 (0.03 mg/kg CIVI) on day-1-60 and MMF
(15 mg/kg) day 1-28. Five HD age 13-21 yrs, 2 stage IIA, 1
stage IIIB, 1 stage IVA, 1 stage IVB and 1 stage III ALCL, age 11,
have been treated. MA AutoSCT  RI AlloSCT were well toler-
ated in all patients. Median time to RI AlloSCT after MA Auto-
SCT was 121 d. Median F/U is 577 d. Toxicity: grade 3 hematuria
(n  1), grade 3/4 infection without neutropenia (n  3), grade 4
infection with neutropenia (n  2), grade 4 pulmonary ﬁbrosis
(n 1), grade 4 hearing loss (n 1) and grade 4 thrombocytopenia
(n  1). Following RI AlloSCT, myeloid recovery occurred on day
15 (MRD), day 18, 23, 15, 30, 45 days (UCBT), plate-
let recovery on day 11 (MRD), day 31, 170, 25, 62, NE
(UCBT). All patients achieved 100% donor chimerism by d180.
HD patients: 4/5 are NED at d 837, 836, 632 (deceased) and
147, respectively, 1/5 PD d 175. NHL: NED at d 522. One
patient developed grade II AGVHD of the gut which resolved with
steroids. One patient developed limited CGVHDwhich responded
to alternating CSA  Pred. One pt developed extensive CGVHD.
There has been one death (NRM) from infection d 632. The
estimated OS at 1 year is 100%. In summary, MA  AutoSCT
followed by IFRT, targeted monoclonal antibody therapy, and RI
AlloSCT is feasible and well tolerated in pediatric patients with
relapsed HD/NHL. A larger controlled study with longer follow
up is required to determine if this approach will reduce relapse
and/or long-term toxicity and improve EFS.
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PERSISTENTLY LOW SERUM OSTEOPROTEGRIN LEVELS DURING THE
TREATMENT OF MULTIPLE MYELOMA PATIENTS PREDICTS WORSE
EVENT-FREE SURVIVAL
Moreb, J.S., Zucali, J.R., Roberts, C. University of Florida, Gainesville,
FL
Osteoprotegrin (OPG) functions as a secreted inhibitor of bone
resorption and its serum levels have been reported to be reduced in
patients with multiple myeloma (MM). In this study, serum and
urine OPG levels were prospectively measured in patients with
MM (stage II III) and in patients with other hematologic malig-
nancies (control group) and correlated to response to therapy.
Newly diagnosed as well as patients on maintenance therapy were
included. The MM and control group were well matched in terms
of age and gender, as well as time from diagnosis to enrollment.
Seventeen MM patients underwent autologous stem cell transplant
while none in the control group were transplanted. Blood and
urine samples were collected monthly, cytocentrifuged and stored
in frozen aliquots at 20° C until analyzed. OPG was measured
using an ELISA. Thus far data on 28 MM patients and 9 patients
with other hematologic malignancies (2 AML, 2 CML, 1 CLL, 2
NHL, 2 monoclonal gammopathy of unknown signiﬁcance) have
been analyzed. All patients were treated with monthly intravenous
bisphosphonate. The results reveal that OPG is detectable in the
urine and its levels correlate signiﬁcantly (r  0.77 and two-tailed
P  0.0032) with the degree of renal failure as reﬂected by serum
creatinine. Our results also show that the overall median serum
OPG level was lower in MM patients (1181 pg/mL), but not
signiﬁcantly different than that of the control group (1437 pg/mL).
However, 4 of 20 (20%) evaluable MM patients with adequate
follow-up had OPG serum levels that remained  1000 pg/mL
throughout the treatment. Their median event-free survival (EFS)
was 8 months compared with 19 months for the rest of the group
(P  0.023), while no signiﬁcant difference was detected in the
median overall survival. There was no OPG serum levels  1000
pg/mL during the follow-up of the control group. Among the 10
newly diagnosed MM patients enrolled in the study, only 2 (20%)
had low serum OPG at presentation, with no detectable urine
OPG. Median OPG serum levels were lower for MM patients
during induction therapy (940 pg/mL, n  7) in comparison to
those undergoing maintenance therapy (1536 pg/mL, n  8; P 
0.16). In conclusion, OPG urine as well as serum levels should be
monitored simultaneously since low serum levels may reﬂect high
OPG urinary loss. In addition, persistently low OPG serum levels
throughout treatment of MM patients may be a prognostic factor
for worse EFS.
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ASCT IN A YOUNG PATIENT WITH FEATURES OF POEMS SYNDROME
EVOLVING TO MULTIPLE MYELOMA
Roesler, W., Guenther, A., Schub, N., Winkler, J., Rascu, A., Repp, R.,
Gramatzki, M. Div. of Hematology/Oncology, Department of Medicine
III, University of Erlangen-Nuremberg, Erlangen, Germany
POEMS syndrome is a rare plasma cell dyscrasia characterised by
polyneuropathy, organomegaly, endocrinopathy, monoclonal
gammopathy and skin changes. The pathogenesis of the disease is
unclear. However, certain features are similar to multicentric
Castleman’s disease and HHV-8 infection. We report the case of a
patient with POEMS syndrome progressing to multiple myeloma
that was unresponsive to treatment with rituximab and standard
chemotherapy but improved considerably after ASCT. The 28 year
old patient presented with severe polyneuropathy. A low level IgG
lamda monoclonal gradient and a slight plasma cell inﬁltration of
the marrow was found. Hepatosplenomegaly, thrombocytosis,
polycythemia, plethora and low TSH was consistent with POEMS
syndrome. The patient had anti-HHV-8 antibodies and HHV-8-
DNA was found in her initial marrow examination. While reported
to be effective in Castleman’s disease, the patient was treated with
4 doses of rituximab, but did not respond. During the following 3
months the patient progressed to multiple myeloma with a bone
marrow involvement of  20% plasma cells. Atypical plasma cells
and a hypercellular megakaryopoesis were found. However, no
Table. Preliminary Results of Gallium-67 Scintigraphic Study on
Major Salivary Glands (n  18 patients)
Submandible
(n patients)
Parotid
(n patients)
Positive Negative Positive Negative
Before BMT 1 17 0 18
Day 30 after 5 9 3 11
Day  60 after 7 6 3 10
Day  100 after 7 6 4 9
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